BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) COO Kenneth Kovan tells Proactive that cancer vaccine manufacturing partner Bio Elpida has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine.
Kovan says the Lyon, France-based company has completed the technology process transfer with BioVaxys and started the development phase using a ‘quality by design' approach. which includes establishing the control methods and manufacturing process development.